PRAMOSONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRAMOSONE (PRAMOSONE).
Pramoxine acts as a local anesthetic by reversibly blocking sodium channels in nerve cell membranes, reducing neuronal membrane permeability to sodium ions and thereby inhibiting the initiation and conduction of nerve impulses. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating immune cell activity.
| Metabolism | Pramoxine: Primarily metabolized in the liver via oxidative deamination and conjugation; Hydrocortisone: Primarily hepatic via CYP3A4 to inactive metabolites such as tetrahydrocortisone and 17-oxosteroids. |
| Excretion | Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites and parent compound. |
| Half-life | Terminal half-life: 3-4 hours for pramoxine; clinical context: short duration requiring frequent application; in hepatic impairment, may be prolonged. |
| Protein binding | Approximately 70-80% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<5%); rectal: <10% due to local metabolism and first-pass effect. |
| Onset of Action | Topical: within 1-2 minutes; rectal: within 5 minutes. |
| Duration of Action | Topical: 2-4 hours; rectal: 3-6 hours; note: duration may be shorter in inflamed mucosa. |
Topical: Apply thin layer to affected area 3-4 times daily. Rectal: Insert 1 suppository (2% pramoxine HCl and 1% hydrocortisone acetate) rectally twice daily (morning and evening).
| Dosage form | LOTION |
| Renal impairment | No dosage adjustment required for topical or rectal use. |
| Liver impairment | No dosage adjustment required for topical or rectal use. |
| Pediatric use | Safety and efficacy not established; use only if clearly needed. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic absorption; apply sparingly to limited areas. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRAMOSONE (PRAMOSONE).
| Breastfeeding | Systemic corticosteroids are excreted in breast milk in low amounts. Pramoxine is a local anesthetic with minimal systemic absorption. No specific lactation data for this combination. M/P ratio not available. Consider risk-benefit; avoid application to breast area to prevent infant ingestion. |
| Teratogenic Risk | Pramosome (pramoxine 1% and hydrocortisone 1%) is a topical combination. No well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Topical corticosteroids, in general, have been associated with low birth weight and cleft palate after systemic absorption at high doses. However, topical application minimizes systemic exposure. Risk to fetus cannot be ruled out; use only if clearly needed and guided by clinical assessment. Trimester-specific risks are not established. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pramoxine, hydrocortisone, or any component of the formulation. Presence of fungal, bacterial, or viral infections (e.g., herpes simplex, vaccinia) in the area of application. Perforation or fistula of the rectum.
| Precautions | Do not exceed recommended dosage or duration of use. Avoid contact with eyes. In case of rectal bleeding or persistent symptoms, discontinue use and consult a physician. Use with caution in patients with rectal mucositis or fecal impaction. Prolonged use of corticosteroids may lead to systemic absorption and adrenal suppression or skin atrophy. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical use. Monitor for signs of HPA axis suppression with prolonged use (especially if large areas or occlusive dressings are used). No fetal monitoring indicated. |
| Fertility Effects | No known effects on fertility. Topical corticosteroids and anesthetics have not been shown to impair reproductive function in humans. |